Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab PK and Safety Study in Healthy Japanese Participants
NCT05304130Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of otilimab in rheumatoid arthritis (RA), sponsored by GSK. Primary endpoints: Maximum drug concentration up to 8 Weeks and Area under the concentration-time curve from pre-dose to infinity up to 8 Weeks. Planned start Feb 2023; status: withdrawn.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05304130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304130.